Legacy MEDSearch

SEPTEMBER 18, 2023

Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) supplement to permit the expansion of the study of the eShunt System in patients with Normal Pressure Hydrocephalus (NPH) to additional study participants and clinical sites. . CereVasc, Inc., Carl Heilman, M.D., and Adel Malek, M.D., Are you hiring?

Food and Drug Administration 52

Food and Drug Administration FDA Patients Recruitment 52

Legacy MEDSearch

AUGUST 29, 2022

Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application to initiate a pilot trial of the eShunt ® System in patients who develop communicating hydrocephalus post aneurysmal subarachnoid hemorrhage (paSAH). . CereVasc, Inc., Press Release by: CereVasc. Are you hiring?

FDA 52

FDA Food and Drug Administration Recruitment Physicians 52

Legacy MEDSearch

JULY 27, 2022

Rapid Medical , a leading developer of advanced neurovascular devices, announces FDA 510(k) clearance for TIGERTRIEVER 13 for large vessel occlusions at the 2022 Society of NeuroInterventional Surgery’s (SNIS) 19th Annual Meeting in Toronto. The ability to tailor each procedure can provide new safety levels for higher-risk thrombectomies.

Medical 52

Medical FDA Recruitment Physicians 52

Legacy MEDSearch

AUGUST 23, 2023

Food and Drug Administration (FDA) Circulatory Systems Devices Panel of the Medical Devices Advisory Committee met to discuss the pre-market approval application (PMA) for the Paradise Ultrasound Renal Denervation (RDN) system, indicated to reduce blood pressure in patients with hypertension. Otsuka Medical Devices”) announce the U.S.

Medical 52

Medical Food and Drug Administration FDA Recruitment 52

Legacy MEDSearch

FEBRUARY 28, 2023

In addition, pooled analysis results from the combined primary efficacy endpoint and safety data from RADIANCE SOLO, RADIANCE TRIO, and RADIANCE II were concurrently published in JAMA Cardiology. The study also achieved its primary safety composite outcome with no major adverse events observed. mmHg, compared to a reduction of -1.8

Networking 98

Networking Medical Physicians Safety 98

Legacy MEDSearch

JUNE 28, 2023

4-7 Vbeam 595 nm PDL treatment during infancy can be done without general anesthesia, which offers a safety advantage over repeated treatments performed under general anesthesia, and it can maximize the likelihood of clearance with frequent but safe treatment sessions. ”, states board-certified cosmetic dermatologist, Roy G. .”,

Medical 52

Medical FDA Recruitment Side effects 52

Pharmaceutical Technology

MARCH 24, 2023

Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year. In addition, two more Humira biosimilars are currently under FDA review and both are anticipated to launch in 2023.

Competition 59

Competition Marketing FDA Physicians 59

Legacy MEDSearch

JULY 21, 2023

“We are addressing the observations by so many physicians that there is a vast unmet need for a better way to definitively treat this female population.” This first-in-female procedure was approved by the National Agency for the Safety of Medicines and Health Products (or ANSM, the French equivalent to the U.S.

Food and Drug Administration 52

Food and Drug Administration Patients Safety Recruitment 52

Pharmaceutical Technology

JANUARY 10, 2023

The erosion of Januvia is due to patent expiry in that had been expected in 2022 and physicians’ preference for sodium-glucose linked transporter-2 inhibitor (SGLT-2I) therapies such as Farxiga (dapagliflozin) and Jardiance (empagliflozin) due to their ability to improve glycemic control and address cardiorenal comorbidities.

Marketing 52

Marketing Physicians Leads Sales 52

European Pharmaceutical Review

NOVEMBER 8, 2022

For example, the US recently passed the Inflation Reduction Act, 1 which requires the Secretary of Health and Human Services (HHS) to negotiate prices for certain physician-administered and retail prescription drugs covered under Medicare Parts B and D. Citizen Petitions before the FDA. 5) monitoring access to biosimilars.

Food and Drug Administration 52

Food and Drug Administration Pharma Prescription Manufacturing 52

Legacy MEDSearch

OCTOBER 25, 2023

Theranica , a neuromodulation therapeutics company, announced the publication of a comprehensive clinical study in Advances in Therapy examining the long-term utilization, clinical efficacy, and safety of Nerivio ® , a Remote Electrical Neuromodulation (REN) device for the treatment of migraine.

Side effects 52

Side effects Recruitment Networking Management 52

Legacy MEDSearch

MAY 23, 2022

He is a former assistant team physician to The Cleveland Guardians and Cleveland Cavaliers. The company has raised more than $18 million to date from institutional investors, family offices, and more than 50 physician champions. 2015) designs devices to set new operating-room standards for efficiency and patient safety.

Food and Drug Administration 52

Food and Drug Administration Medicine Recruitment Physicians 52

Clarify Health

JULY 13, 2020

However, approximately two-thirds of new drugs fall short of first-year sales expectations. They narrowed the eligibility criteria, much beyond what was approved by the FDA. Despite their efficacy and safety, the high cost and lifetime use made payers put up barriers to exclude the drug on formulary.

Pharmaceutical 52

Pharmaceutical Pharma Patients Marketing 52

pharmaphorum

JULY 6, 2022

Some patients with COVID-19 will be able to get easier access to Pfizer’s oral antiviral therapy Paxlovid, after the FDA ruled that pharmacists would be able to prescribe the drug. Now, in addition to doctors and providers, the FDA announced pharmacists with your medical information can prescribe Paxlovid to patients. It made $1.5

FDA 91

FDA Doctors Side effects Patients 91

Legacy MEDSearch

MAY 1, 2023

the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB. Results from the trial are under review by the FDA. BlueWind Medical, Ltd.,

Patients 52

Patients Medical Safety Recruitment 52

Pharmaceutical Technology

AUGUST 8, 2022

In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. Yet, despite the landmark FDA approval, digital pills have not exploded in pharma. Proteus Health’s Abilify MyCite had an ingestible sensor that could track if a patient consumed the drug.

Food and Drug Administration 122

Food and Drug Administration FDA Medicine Patients 122

Legacy MEDSearch

JULY 19, 2023

“We would like to thank our employees, investors, patients, and physician partners for bringing us to this stage. ” The company anticipates using the one-year follow-up data from the VAPOR 2 study in support of an FDA submission for U.S. Francis Medical, Inc., clinical sites. . market clearance.

Medical 52

Medical Side effects Patients Recruitment 52

Legacy MEDSearch

SEPTEMBER 27, 2023

Its flagship product, the Personal Cardiac Assistant (PCA 500) , is the only hospital-grade, resting 12-lead ECG device cleared by the FDA and CE marked for both professional and patient use. QT Medical aims to provide improved cardiac devices and services to revolutionize the care of patients with heart disease.

Medical 52

Medical Recruitment Leads Management 52

Legacy MEDSearch

NOVEMBER 10, 2022

The results were presented at the 2022 American Heart Association (“AHA”) annual meeting by Dr. Ajay Kirtane, Professor of Medicine at Columbia University, Vagelos College of Physicians and Surgeons and an interventional cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center. mmHg (p<0.0001), favoring uRDN.

Medical 94

Medical Recruitment Patients Management 94

Legacy MEDSearch

AUGUST 11, 2022

OSSIOfiber Suture Anchors were FDA cleared in March 2022 for use in “fixation of suture (soft tissue) to bone in the shoulder, foot/ankle, knee, hand/wrist, and elbow” in a variety of specific orthopedic procedures. OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians and payors.

Recruitment 52

Recruitment Marketing Safety Medical 52